Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	75 people; 75 eyes with rhegmatogenous retinal detachment (RRD) and grade C proliferative vitreoretinopathy (PVR)	Intraocular pressure 6 months 14.7 mmHg with triamcinolone acetonide 16.4 mmHg with no triamcinolone acetonide	P = 0.25		Not significant
RCT	75 people; 75 eyes with RRD and grade C PVR	Recurrence of PVR 6 months 11/38 (29%) with triamcinolone acetonide 11/37 (37%) with no triamcinolone acetonide	P = 0.94		Not significant
RCT	75 people; 75 eyes with RRD and grade C PVR	Macular pucker 6 months 8/38 (21%) with triamcinolone acetonide 13/37 (35%) with no triamcinolone acetonide	P = 0.2		Not significant
RCT	220 people with RRD (220 consecutive eyes) having sclera buckling procedure plus air or SF6 gas in around 50% of eyes plus primary vitrectomy in around 14% of eyes; posterior Nd:Yag capsulotomy in around 9% of eyes; 79.5% phakic	Post-operative PVR stage A at 1 month 5/106 (5%) with oral prednisone tapering for 15 days 7/99 (7%) with placebo	Reported as not significant		Not significant
RCT	220 people with RRD (220 consecutive eyes) having sclera buckling procedure plus air or SF6 gas in around 50% of eyes plus primary vitrectomy in around 14% of eyes; posterior Nd:Yag capsulotomy in around 9% of eyes; 79.5% phakic	Post-operative PVR stage B at 1 month 28/106 (26%) with oral prednisone tapering for 15 days 40/99 (40%) with placebo	P <0.05	Effect size not calculated	prednisone
RCT	220 people with RRD (220 consecutive eyes) having sclera buckling procedure plus air or SF6 gas in around 50% of eyes plus primary vitrectomy in around 14% of eyes; posterior Nd:Yag capsulotomy in around 9% of eyes; 79.5% phakic	Post-operative PVR stage C at 1 month 5/106 (5%) with oral prednisone tapering for 15 days 3/99 (3%) with placebo	Reported as not significant		Not significant
RCT	220 people with RRD (220 consecutive eyes) having sclera buckling procedure plus air or SF6 gas in around 50% of eyes plus primary vitrectomy in around 14% of eyes; posterior Nd:Yag capsulotomy in around 9% of eyes; 79.5% phakic	Post-operative PVR stage A at 3 months 6/107 (6%) with oral prednisone tapering for 15 days 4/99 (4%) with placebo	Reported as not significant		Not significant
RCT	220 people with RRD (220 consecutive eyes) having sclera buckling procedure plus air or SF6 gas in around 50% of eyes plus primary vitrectomy in around 14% of eyes; posterior Nd:Yag capsulotomy in around 9% of eyes; 79.5% phakic	Post-operative PVR stage B at 3 months 27/107 (25%) with oral prednisone tapering for 15 days 45/99 (46%) with placebo	P <0.005	Effect size not calculated	prednisone
RCT	220 people with RRD (220 consecutive eyes) having sclera buckling procedure plus air or SF6 gas in around 50% of eyes plus primary vitrectomy in around 14% of eyes; posterior Nd:Yag capsulotomy in around 9% of eyes; 79.5% phakic	Post-operative PVR stage C at 3 months 3/107 (3%) with oral prednisone tapering for 15 days 2/99 (2%) with placebo	Reported as not significant		Not significant
RCT	220 people with RRD (220 consecutive eyes) having sclera buckling procedure plus air or SF6 gas in around 50% of eyes plus primary vitrectomy in around 14% of eyes; posterior Nd:Yag capsulotomy in around 9% of eyes; 79.5% phakic	Post-operative PVR stage A at 6 months 1/102 (1%) with oral prednisone tapering for 15 days 4/94 (4%) with placebo	Reported as not significant		Not significant
RCT	220 people with RRD (220 consecutive eyes) having sclera buckling procedure plus air or SF6 gas in around 50% of eyes plus primary vitrectomy in around 14% of eyes; posterior Nd:Yag capsulotomy in around 9% of eyes; 79.5% phakic	Post-operative PVR stage B at 6 months 23/102 (23%) with oral prednisone tapering for 15 days 43/94 (46%) with placebo	P <0.0005	Effect size not calculated	prednisone
RCT	220 people with RRD (220 consecutive eyes) having sclera buckling procedure plus air or SF6 gas in around 50% of eyes plus primary vitrectomy in around 14% of eyes; posterior Nd:Yag capsulotomy in around 9% of eyes; 79.5% phakic	Post-operative PVR stage C at 6 months 2/102 (2%) with oral prednisone tapering for 15 days 3/94 (3%) with placebo	Reported as not significant		Not significant